Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.

Carissa Beaulieu, Naveen S. Basappa, Camilla Tajzler et al.|Journal of Clinical Oncology|2024

Cited by 1